<div id="readability-page-1"><p><span>Alignment Healthcare (NASDAQ:ALHC - Get Free Report)</span> had its price objective upped by JPMorgan Chase &amp; Co.  from $17.00 to $18.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a &#34;neutral&#34; rating on the stock. JPMorgan Chase &amp; Co.'s price target indicates a potential upside of 5.51% from the stock's previous close.</p><p>A number of other research analysts have also recently issued reports on ALHC. Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of Alignment Healthcare in a research note on Wednesday, October 8th. Wall Street Zen lowered Alignment Healthcare from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Sunday, August 10th. The Goldman Sachs Group  reissued a &#34;buy&#34; rating and issued a $22.00 target price on shares of Alignment Healthcare in a report on Monday. UBS Group lifted their target price on Alignment Healthcare from $17.00 to $18.00 and gave the stock a &#34;neutral&#34; rating in a report on Friday, October 31st. Finally, Barclays lifted their target price on Alignment Healthcare from $13.00 to $18.00 and gave the stock an &#34;equal weight&#34; rating in a report on Friday, October 31st. One analyst  has rated the stock with a Strong Buy rating, seven have issued  a Buy rating, four have assigned  a Hold rating and one  has given a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $19.85.</p><div><p><span></span><span>Get <strong>Alignment Healthcare</strong> alerts:</span></p></div><p><b>Get Our Latest Stock Analysis on ALHC</b></p><h2>Alignment Healthcare Price Performance</h2><p>Shares of Alignment Healthcare stock traded down $0.03 during trading on Wednesday, hitting $17.06. 1,392,839 shares of the stock traded hands, compared to its average volume of 3,112,505. The company has a quick ratio of 1.61, a current ratio of 1.61 and a debt-to-equity ratio of 1.99. The stock has a market cap of $3.41 billion, a price-to-earnings ratio of -142.13 and a beta of 1.17. The firm's fifty day moving average is $16.94 and its 200-day moving average is $15.46. Alignment Healthcare has a 52 week low of $10.18 and a 52 week high of $21.06. </p><p>Alignment Healthcare (NASDAQ:ALHC - Get Free Report) last posted its quarterly earnings results on Thursday, October 30th. The company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $0.03. Alignment Healthcare had a negative return on equity of 16.23% and a negative net margin of 0.57%.The business had revenue of $993.70 million for the quarter, compared to analyst estimates of $980.90 million. During the same period last year, the company earned ($0.14) EPS. Alignment Healthcare's revenue for the quarter was up 43.5% compared to the same quarter last year.  Alignment Healthcare has set its FY 2025 guidance at  EPS. Q4 2025 guidance at  EPS. Research analysts expect that  Alignment Healthcare will post -0.69 EPS for the current fiscal year. </p><h2>Insider Buying and Selling</h2><p>In other Alignment Healthcare news, insider Hyong Kim sold 51,379 shares of the stock in a transaction dated Thursday, October 9th. The stock was sold at an average price of $17.57, for a total transaction of $902,729.03. Following the sale, the insider directly owned 362,333 shares of the company's stock, valued at approximately $6,366,190.81. This trade represents a 12.42% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. Also, Director Atlantic (Aln Hlth) L. General sold 6,246,096 shares of the firm's stock in a transaction dated Wednesday, September 17th. The shares were sold at an average price of $16.01, for a total value of $99,999,996.96. Following the sale, the director owned 24,596,079 shares in the company, valued at $393,783,224.79. This trade represents a 20.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 7,427,716 shares of company stock valued at $119,650,069 over the last 90 days. 6.60% of the stock is owned by insiders. </p><h2>Institutional Trading of Alignment Healthcare</h2><p>Several institutional investors have recently made changes to their positions in the company. Principal Financial Group Inc. grew its stake in shares of  Alignment Healthcare by 40.1% in the third quarter. Principal Financial Group Inc. now owns 167,376 shares of the company's stock worth $2,921,000 after acquiring an additional 47,895 shares in the last quarter.  Arizona State Retirement System grew its stake in shares of  Alignment Healthcare by 33.1% in the third quarter. Arizona State Retirement System now owns 40,967 shares of the company's stock worth $715,000 after acquiring an additional 10,195 shares in the last quarter.  New York State Common Retirement Fund grew its stake in shares of  Alignment Healthcare by 3.1% in the third quarter. New York State Common Retirement Fund now owns 207,461 shares of the company's stock worth $3,620,000 after acquiring an additional 6,200 shares in the last quarter.  Vanguard Personalized Indexing Management LLC acquired a new position in shares of  Alignment Healthcare in the third quarter worth $242,000.  Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of  Alignment Healthcare in the third quarter worth $3,499,000. Hedge funds and other institutional investors own  86.19% of the company's stock. </p><h2>Alignment Healthcare Company Profile</h2> (Get Free Report)<p>Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Alignment Healthcare</li><li>Asset Allocation Strategies in Volatile Markets</li><li>Spotify Posts Huge EPS Beat: Shares Are Still Down Big From Highs</li><li>The 3 Best Blue-Chip Stocks to Buy Now</li><li>Stardust's Strategic Lithium Deal Could Be a Game-Changer</li><li>How to Calculate Stock Profit </li><li>Sticker Shock: Why Kimberly-Clark's Sell-Off Is an Overreaction</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxIQw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxIQw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Alignment Healthcare Right Now?</h2><p>Before you consider Alignment Healthcare, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alignment Healthcare wasn't on the list.</p><p>While Alignment Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ALHC

<p>JPMorgan Chase & Co. has raised its target price for Alignment Healthcare (NASDAQ:ALHC) from $17.00 to $18.00, maintaining a "neutral" rating. This indicates a potential upside of 5.51% from the previous close. Other analysts have mixed ratings, with Weiss Ratings issuing a "sell" and Goldman Sachs a "buy" with a $22.00 target. The stock traded at $17.06, with a market cap of $3.41 billion. Recent insider sales and institutional investments reflect ongoing interest in the company, which reported a 43.5% revenue increase year-over-year.</p>

JPMorgan Chase & Co. Issues Positive Forecast for Alignment Healthcare (NASDAQ:ALHC) Stock Price